Azenta (NASDAQ:AZTA) Research Coverage Started at Zacks Research

Zacks Research started coverage on shares of Azenta (NASDAQ:AZTA) in a research note published on Thursday,Zacks reports. The firm issued a hold rating on the stock.

A number of other research firms also recently weighed in on AZTA. Jefferies Financial Group lifted their price target on Azenta from $44.00 to $52.00 and gave the company a “buy” rating in a research note on Wednesday. Needham & Company LLC upped their price objective on Azenta from $37.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 26th. Finally, Wall Street Zen upgraded Azenta from a “hold” rating to a “buy” rating in a research report on Saturday. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $47.60.

Azenta Stock Performance

AZTA traded up $1.79 during trading on Thursday, reaching $45.65. The company’s stock had a trading volume of 1,114,037 shares, compared to its average volume of 964,725. Azenta has a 52-week low of $15.93 and a 52-week high of $50.06. The company’s fifty day moving average price is $36.52 and its 200-day moving average price is $28.56. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -12.61 and a beta of 1.47.

Azenta (NASDAQ:AZTA) last released its earnings results on Tuesday, November 10th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.17. The company had revenue of $167.09 million for the quarter, compared to analysts’ expectations of $160.16 million. Azenta had a positive return on equity of 1.41% and a negative net margin of 26.86%. Equities analysts predict that Azenta will post 0.69 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Azenta in the second quarter valued at about $192,152,000. GW&K Investment Management LLC lifted its position in shares of Azenta by 0.4% during the 3rd quarter. GW&K Investment Management LLC now owns 992,616 shares of the company’s stock valued at $34,633,000 after acquiring an additional 4,187 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Azenta by 16.3% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,613,914 shares of the company’s stock valued at $34,183,000 after acquiring an additional 225,867 shares during the period. Front Street Capital Management Inc. purchased a new stake in shares of Azenta during the 2nd quarter worth approximately $33,212,000. Finally, American Capital Management Inc. boosted its stake in shares of Azenta by 26.9% during the 1st quarter. American Capital Management Inc. now owns 1,296,024 shares of the company’s stock worth $27,385,000 after acquiring an additional 274,588 shares in the last quarter. 99.08% of the stock is currently owned by institutional investors and hedge funds.

More Azenta News

Here’s some of the latest news about AZTA:

• Positive Sentiment: Needham raised its price target to $57 from $37 and maintained a Buy rating, signaling greater optimism about potential upside. Article: Needham Raises Azenta Price Target
• Positive Sentiment: Coverage highlighted commercial execution and new gene-synthesis capabilities as factors supporting Azenta’s outlook. KeyCorp’s estimates call for $0.69 EPS in FY2027 and $0.84 in FY2028; these are analyst forecasts, not company guidance. Article: Azenta Q3 Deep Dive
• Negative Sentiment: Rosen Law Firm said it is investigating potential securities claims tied to allegations that Azenta may have issued materially misleading business information. The investigation is an allegation, not a finding of wrongdoing, but may weigh on sentiment. Article: Rosen Law Firm Investor Notice

About Azenta

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.